Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera,Cell

当前位置： X-MOL 学术 › Cell › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Cell ( IF 64.5 ) Pub Date : 2021-02-18 , DOI: 10.1016/j.cell.2021.02.033
Piyada Supasa ₁ , Daming Zhou ₂ , Wanwisa Dejnirattisai ₁ , Chang Liu ₃ , Alexander J Mentzer ₄ , Helen M Ginn ₅ , Yuguang Zhao ₂ , Helen M E Duyvesteyn ₂ , Rungtiwa Nutalai ₁ , Aekkachai Tuekprakhon ₁ , Beibei Wang ₁ , Guido C Paesen ₂ , Jose Slon-Campos ₁ , César López-Camacho ₁ , Bassam Hallis ₆ , Naomi Coombes ₆ , Kevin R Bewley ₆ , Sue Charlton ₆ , Thomas S Walter ₂ , Eleanor Barnes ₇ , Susanna J Dunachie ₈ , Donal Skelly ₉ , Sheila F Lumley ₁₀ , Natalie Baker ₆ , Imam Shaik ₆ , Holly E Humphries ₆ , Kerry Godwin ₆ , Nick Gent ₆ , Alex Sienkiewicz ₆ , Christina Dold ₁₁ , Robert Levin ₁₂ , Tao Dong ₁₃ , Andrew J Pollard ₁₁ , Julian C Knight ₁₄ , Paul Klenerman ₇ , Derrick Crook ₁₅ , Teresa Lambe ₁₆ , Elizabeth Clutterbuck ₁₁ , Sagida Bibi ₁₁ , Amy Flaxman ₁₆ , Mustapha Bittaye ₁₆ , Sandra Belij-Rammerstorfer ₁₆ , Sarah Gilbert ₁₆ , David R Hall ₅ , Mark A Williams ₅ , Neil G Paterson ₅ , William James ₁₇ , Miles W Carroll ₁₈ , Elizabeth E Fry ₂ , Juthathip Mongkolsapaya ₁₉ , Jingshan Ren ₂ , David I Stuart ₂₀ , Gavin R Screaton ₃

Affiliation

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Worthing Hospital, Worthing, UK.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Sir William Dunn School of Pathology University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK; Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.

中文翻译：

恢复期血清和疫苗血清对 SARS-CoV-2 B.1.1.7 变体的中和作用减少

SARS-CoV-2 在一年多的时间里已导致超过 200 万人死亡。疫苗正在大规模部署，旨在针对病毒激增做出反应。大流行的规模和容易出错的病毒复制正在导致突变病毒的出现，并可能逃避抗体反应。变体 B.1.1.7 目前在英国占主导地位，传播增加，在尖峰中包含 9 个氨基酸变化，包括 ACE2 相互作用表面中的 N501Y。我们检查了 B.1.1.7 逃避自然 SARS-CoV-2 感染或疫苗接种引起的抗体反应的能力。我们通过对大量已充分表征的单克隆抗体进行结构/功能分析来绘制 N501Y 的影响。B.1.1.7 比亲代病毒更难中和，通过与残基 501 的轻链接触，损害了主要类别公共抗体的一些成员的中和作用。然而，单克隆抗体或自然感染或疫苗接种产生的抗体反应的广泛逃逸没有观察到。

更新日期：2021-04-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>